Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion.

Background: Faricimab, the new anti-vascular endothelial growth factor (VEGF) drug including a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has emerged as a therapeutic option for macular edema secondary to retinal vein occlusion (RVO), and its efficacy has been demonstrated in randomized controlled trials (RCTs); however, reports on its use in clinical practice are still limited. This study was conducted to evaluate the real-world treatment outcomes of faricimab for macular edema secondary to RVO, managed with a single initial injection plus pro re nata (1 + PRN) approach in both treatment-naïve and previously treated patients who switched to this regimen.

Methods: This retrospective observational study included patients diagnosed with branch or central RVO, who received intravitreal faricimab therapy following the 1 + PRN protocol.

Visual outcome after emergency surgery for open globe eye injury in Japan.

Background: Most patients with open globe eye injury are brought to hospital as emergency patients and usually require admission for emergency surgery. We analyzed the visual outcome in patients with open globe eye injury at our hospital over a 4-year period.

Patients And Methods: This study reviewed 40 eyes of 40 patients with open globe eye injury who were presented to Juntendo University Shizuoka Hospital and required emergency surgery during the 4 years from January 2010 to December 2014.